Der Onkologe

, Volume 13, Issue 8, pp 745–758 | Cite as

Kutanes Melanom

  • T.K. Eigentler
  • L.-O. Mügge
  • A. Bembenek
  • C. Garbe
CME Weiterbildung • Zertifizierte Fortbildung
  • 66 Downloads

Zusammenfassung

Während die Inzidenz des kutanen Melanoms (CM) ständig steigt, haben sich die Mortalitätszahlen stabilisiert. Risikofaktoren für die CM-Entwicklung sind Exposition gegenüber UV-Licht und individuelle Merkmale des Pigmentsystems, v. a. die Anzahl melanozytärer Nävi. Der entscheidende prognostische Faktor ist die vertikale Tumordicke am histologischen Präparat. Die Exzision des Primärtumors mit angepasstem Sicherheitsabstand ist die Therapie der Wahl. Ab einer Tumordicke von 1,0 mm wird eine Wächterlymphknotenbiopsie empfohlen. In der adjuvanten Situation zeigte nur Interferon-α in prospektiv randomisierten Studien einen signifikanten Vorteil. Die Therapie bei Fernmetastasierung ist palliativ. Primär wird versucht, durch operative, radiologische und chemotherapeutische Maßnahmen eine Remission zu erreichen. Als systemische Standardtherapie ist am ehesten die Dacarbazinmonochemotherapie anzusehen. Die Nachsorge orientiert sich an den initialen Tumordaten sowie am aktuellen Stadium.

Schlüsselwörter

Malignes Melanom Inzidenz Primärexzision Adjuvante/palliative Therapie Nachsorge 

Cutaneous melanoma

Abstract

While the incidence of cutaneous melanoma (CM) continues to rise steadily, the mortality has stabilized. Risk factors for the development of CM are UV light exposure and individual characteristics relating to pigmentation, and especially the number of melanocytic nevi. The most important prognostic factor in CM is the vertical thickness of the primary tumor in the histological specimen. Excision of the primary tumor with adequate safety margins is the treatment of choice. In the case of a tumor 1.0 mm or more thick biopsy of the sentinel node is recommended. Interferon-α is currently the only adjuvant therapy shown to have significant benefit in prospective randomized trials. When distant metastases are present treatment is palliative and is aimed primarily at achieving tumor remission by operative, radiological, and pharmacological means. Dacarbazine is considered the standard drug for systemic treatment. Follow-up depends on the initial tumor parameters and the current stage of the disease.

Keywords

Malignant melanoma Incidence Excision of the primary tumor Adjuvant/palliative treatment Follow-up 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Amaravadi RK, Schuchter L, Barth SF et al. (2006) Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. JCO ASCO Annual Meeting Proceedings Part I. 24: 18Google Scholar
  2. 2.
    Armstrong BK, Kricker A (1993) How much melanoma is caused by sun exposure? Melanoma Res 3: 395–401PubMedCrossRefGoogle Scholar
  3. 3.
    Attia P, Phan GQ, Maker AV et al. (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23: 6043–6053PubMedCrossRefGoogle Scholar
  4. 4.
    Balch CM, Buzaid AC, Soong SJ et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635–3648PubMedGoogle Scholar
  5. 5.
    Balch CM, Soong SJ, Gershenwald JE et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622–3634PubMedGoogle Scholar
  6. 6.
    Ballo MT, Strom EA, Zagars GK et al. (2002) Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 52: 964–972PubMedCrossRefGoogle Scholar
  7. 7.
    Bartlett JB, Michael A, Clarke IA et al. (2004) Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90: 955–961PubMedCrossRefGoogle Scholar
  8. 8.
    Bedogni B, O’Neill MS, Welford SM et al. (2004) Topical treatment with inhibitors of the phosphatidylinositol 3’-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 64: 2552–2560PubMedCrossRefGoogle Scholar
  9. 9.
    Büttner PG, Leiter U, Eigentler TK et al. (2005) Development of prognostic factors and survival in cutaneous melanoma over 25 years: an analysis of the central malignant melanoma registry of the German dermatological society. Cancer 103: 616–624CrossRefGoogle Scholar
  10. 10.
    Costanzi JJ, Al-Sarraf M, Groppe C et al. (1982) Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study. Med Pediatr Oncol 10: 251–258PubMedCrossRefGoogle Scholar
  11. 11.
    Creagan ET, Suman VJ, Dalton RJ et al. (1999) Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 17: 1884–1890PubMedGoogle Scholar
  12. 12.
    Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–954PubMedCrossRefGoogle Scholar
  13. 13.
    Eigentler TK, Caroli UM, Radny P et al. (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4: 748–759PubMedCrossRefGoogle Scholar
  14. 14.
    Enk AH, Becker JC, Schuler G (2006) Immunotherapy of malignant melanoma – basic principles and novel therapeutic approaches. J Dtsch Dermatol Ges 4: 635–645PubMedCrossRefGoogle Scholar
  15. 15.
    Facchetti F, Previdi S, Ballarini M et al. (2004) Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9: 573–882PubMedCrossRefGoogle Scholar
  16. 16.
    Falkson CI, Ibrahim J, Kirkwood JM et al. (1998) Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16: 1743–1751PubMedGoogle Scholar
  17. 17.
    Garbe C, Eigentler TK (2007) Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 17: 117–127PubMedCrossRefGoogle Scholar
  18. 18.
    Garbe C, Schadendorf D (2003) Surveillance and follow-up examinations in cutaneous melanoma. Onkologie 26: 241–246PubMedCrossRefGoogle Scholar
  19. 19.
    Garbe C, Hauschild A, Volkenandt M et al. (2005) Das maligne Melanom. In: Garbe C (Hrsg) Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren. Thieme, Stuttgart New YorkGoogle Scholar
  20. 20.
    Goldstein AM, Tucker MA (2001) Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol 137: 1493–1496PubMedGoogle Scholar
  21. 21.
    Gundersen S (1987) Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study. Cancer Treat Rep 71: 997–999PubMedGoogle Scholar
  22. 22.
    Mack LA, McKinnon JG (2004) Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol 86: 189–199PubMedCrossRefGoogle Scholar
  23. 23.
    Margolin K, Longmate J, Baratta T et al. (2005) CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104: 1045–1048PubMedCrossRefGoogle Scholar
  24. 24.
    Markovic SN, Geyer SM, Dawkins F et al. (2005) A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103: 2584–2589PubMedCrossRefGoogle Scholar
  25. 25.
    McClay EF, Mastrangelo MJ, Bellet RE et al. (1987) Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71: 465–469PubMedGoogle Scholar
  26. 26.
    Meier F, Busch S, Lasithiotakis K et al. (2007) Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007Google Scholar
  27. 27.
    Meyer T, Merkel S, Gohl J et al. (2002) Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. Eur J Surg Oncol 28: 424–430PubMedCrossRefGoogle Scholar
  28. 28.
    Miller AJ, Mihm MC (2006) Melanoma. N Engl J Med 355: 51–65PubMedCrossRefGoogle Scholar
  29. 29.
    Möhrle M, Metzger S, Schippert W et al. (2003) „Functional“ surgery in subungual melanoma. Dermatol Surg 29: 366–374CrossRefGoogle Scholar
  30. 30.
    Möhrle M, Dietz K, Garbe C et al. (2006) Conventional histology vs. three-dimensional histology in lentigo maligna melanoma. Br J Dermatol 154: 453–459CrossRefGoogle Scholar
  31. 31.
    Morton DL, Thompson JF, Cochran AJ et al. (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355: 1307–1317PubMedCrossRefGoogle Scholar
  32. 32.
    NN (2006) Phase III trial of nexavar in patients with advanced melanoma does not meet primary endpoint. http://www.onyx-pharm.com/wt/page/pr_1165242111. 04.12.2006
  33. 33.
    Ollila DW (2006) Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol 7: 919–924PubMedCrossRefGoogle Scholar
  34. 34.
    Pectasides D, Yianniotis H, Alevizakos N et al. (1989) Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. Br J Cancer 60: 627–629PubMedGoogle Scholar
  35. 35.
    Peris K, Fargnoli MC, Pacifico A et al. (2004) CDKN2A and MC1R mutations in patients with sporadic multiple primary melanoma. J Invest Dermatol 122: 1327–1330PubMedCrossRefGoogle Scholar
  36. 36.
    Schadendorf D, Ugurel S, Schuler-Thurner B et al. (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17: 563–570PubMedCrossRefGoogle Scholar
  37. 37.
    Thomas JM, Newton-Bishop J, A’Hern R et al. (2004) Excision margins in high-risk malignant melanoma. N Engl J Med 350: 757–766PubMedCrossRefGoogle Scholar
  38. 38.
    Tucker MA, Goldstein AM (2003) Melanoma etiology: where are we? Oncogene 22: 3042–3052PubMedCrossRefGoogle Scholar
  39. 39.
    Veronesi U, Cascinelli N, Adamus J et al. (1988) Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 318: 1159–1162PubMedCrossRefGoogle Scholar
  40. 40.
    Wheatley K, Ives N, Hancock B et al. (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29: 241–252PubMedCrossRefGoogle Scholar
  41. 41.
    York RM, Foltz AT (1988) Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 61: 2183–2186PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  • T.K. Eigentler
    • 1
  • L.-O. Mügge
    • 2
  • A. Bembenek
    • 3
  • C. Garbe
    • 1
  1. 1.Zentrum für Hauttumoren, Südwestdeutsches TumorzentrumUniversitätshautklinik TübingenTübingenDeutschland
  2. 2.Klinik für Innere Medizin IIUniversitätsklinikum JenaJenaDeutschland
  3. 3.Klinik für Chirurgie und Chirurgische Onkologie, Robert-Rössle-KlinikCharité-Universitätsmedizin Berlin, Campus BuchBerlinDeutschland

Personalised recommendations